MCID: SPR005
MIFTS: 40

Superficial Basal Cell Carcinoma

Categories: Cancer diseases

Aliases & Classifications for Superficial Basal Cell Carcinoma

MalaCards integrated aliases for Superficial Basal Cell Carcinoma:

Name: Superficial Basal Cell Carcinoma 12 15 73
Multifocal Superficial Basal Cell Carcinoma 12 73
Superficial Multicentric Basal-Cell Carcinoma 12
Multicentric Basal Cell Carcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4300
NCIt 50 C4108
SNOMED-CT 68 61098004

Summaries for Superficial Basal Cell Carcinoma

MalaCards based summary : Superficial Basal Cell Carcinoma, also known as multifocal superficial basal cell carcinoma, is related to basal cell carcinoma 1 and basal cell carcinoma. An important gene associated with Superficial Basal Cell Carcinoma is TLR7 (Toll Like Receptor 7), and among its related pathways/superpathways are Toll-like Receptor Signaling Pathway and IL-2 Pathway. The drugs Aminolevulinic acid and Methyl 5-aminolevulinate have been mentioned in the context of this disorder. Affiliated tissues include skin and t cells, and related phenotypes are hematopoietic system and immune system

Related Diseases for Superficial Basal Cell Carcinoma

Diseases related to Superficial Basal Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 19)
# Related Disease Score Top Affiliating Genes
1 basal cell carcinoma 1 10.9
2 basal cell carcinoma 10.9
3 squamous cell carcinoma 10.2
4 bowen's disease 10.2
5 keratosis 10.1
6 actinic keratosis 10.0
7 aging 10.0
8 melanoma 10.0
9 scrotum basal cell carcinoma 10.0
10 juvenile nasopharyngeal angiofibroma 9.9 TLR7 TLR9
11 epidermolytic hyperkeratosis 9.8
12 epidermoid cysts 9.8
13 dermatitis 9.8
14 nodular basal cell carcinoma 9.8
15 psoriasis 9.8
16 integumentary system cancer 9.6 PTCH1 TLR9
17 common variable immunodeficiency 9.3 BLK TLR9
18 systemic lupus erythematosus 9.0 BLK TLR7 TLR9
19 viral infectious disease 8.9 TLR7 TLR8 TLR9

Graphical network of the top 20 diseases related to Superficial Basal Cell Carcinoma:



Diseases related to Superficial Basal Cell Carcinoma

Symptoms & Phenotypes for Superficial Basal Cell Carcinoma

MGI Mouse Phenotypes related to Superficial Basal Cell Carcinoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.55 BLK PTCH1 TLR7 TLR8 TLR9
2 immune system MP:0005387 9.35 BLK PTCH1 TLR7 TLR8 TLR9
3 renal/urinary system MP:0005367 8.92 PTCH1 TLR7 TLR8 TLR9

Drugs & Therapeutics for Superficial Basal Cell Carcinoma

Drugs for Superficial Basal Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 32)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aminolevulinic acid Approved Phase 4,Phase 3,Phase 1,Not Applicable 106-60-5 137
2 Methyl 5-aminolevulinate Phase 4,Phase 3,Phase 1,Not Applicable
3 Dermatologic Agents Phase 4,Phase 3,Phase 1,Not Applicable
4 Photosensitizing Agents Phase 4,Phase 3,Phase 1,Not Applicable
5
Imiquimod Approved, Investigational Phase 3,Phase 1 99011-02-6 57469
6 interferons Phase 3,Phase 1
7 Adjuvants, Immunologic Phase 3,Phase 1
8 Interferon Inducers Phase 3,Phase 1
9 Tea Nutraceutical Phase 2, Phase 3
10
Lidocaine Approved, Vet_approved Not Applicable 137-58-6 3676
11
Epinephrine Approved, Vet_approved Not Applicable 51-43-4 5816
12
Racepinephrine Approved Not Applicable 329-65-7 838
13
Vitamin C Approved, Nutraceutical Not Applicable 50-81-7 5785 54670067
14 Respiratory System Agents Not Applicable
15 Central Nervous System Depressants Not Applicable
16 Adrenergic Agents Not Applicable
17 Adrenergic Agonists Not Applicable
18 Adrenergic alpha-Agonists Not Applicable
19 Adrenergic beta-Agonists Not Applicable
20 Mydriatics Not Applicable
21 Sodium Channel Blockers Not Applicable
22 Neurotransmitter Agents Not Applicable
23 Anesthetics Not Applicable
24 Anesthetics, Local Not Applicable
25 Diuretics, Potassium Sparing Not Applicable
26 Vasoconstrictor Agents Not Applicable
27 Anti-Arrhythmia Agents Not Applicable
28 Anti-Asthmatic Agents Not Applicable
29 Peripheral Nervous System Agents Not Applicable
30 Epinephryl borate Not Applicable
31 Autonomic Agents Not Applicable
32 Bronchodilator Agents Not Applicable

Interventional clinical trials:

(show all 22)
# Name Status NCT ID Phase Drugs
1 Superficial Basal Cell Carcinoma Treatment With Topical Photodynamic Therapy With Fractionated 5-aminolevulinic Acid 20% Versus Two Stage Methylaminolevulinate Unknown status NCT01491711 Phase 4 Methylaminolevulinate PDT in 2 sessions;Fractionated 5-aminolevulinic acid hydrochloride 20% gel PDT
2 Open-label Study to Evaluate Clearance of Superficial Basal Cell Carcinoma After Use of Imiquimod 5% Cream Completed NCT00189306 Phase 3 Imiquimod 5% cream
3 Metvix PDT Versus Cryotherapy in Patients With Primary Superficial Basal Cell Carcinoma Completed NCT00469417 Phase 3
4 A Study to Evaluate Effectiveness of Imiquimod 5% Cream in Superficial Basal Cell Carcinoma Completed NCT00189241 Phase 3 imiquimod
5 Topical Green Tea Ointment in Treatment of Superficial Skin Cancer Completed NCT02029352 Phase 2, Phase 3 Sinecatechins 10%;Placebo
6 Topical Imiquimod Compared With Surgery in Treating Patients With Basal Cell Skin Cancer Completed NCT00066872 Phase 3 imiquimod
7 Aldara for the Treatment of Large and/or Multiple sBCC Completed NCT00189280 Phase 3 Imiquimod
8 Radiotherapy or Imiquimod in Complex Lentigo Maligna Recruiting NCT02394132 Phase 3 Imiquimod
9 Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Superficial Basal Cell Carcinoma (sBCC) With Photodynamic Therapy (PDT). Not yet recruiting NCT03573401 Phase 3
10 PEP005 Gel - Evaluation of the Safety and Efficacy of Ingenol Mebutate Gel on a Superficial Basal Cell Carcinoma on the Trunk or Extremities Completed NCT01325688 Phase 2 PEP005 (ingenol mebutate) Gel, 0.05%
11 Dose-Ranging Clinical Trial of Topical Creams Containing API 31510 for the Treatment of Superficial Basal Cell Carcinoma Completed NCT00604890 Phase 2 API 31510 Topical Cream
12 To Determine the Maximum Tolerated Dose Level (MTD) of PEP005 Topical Gel in Patients With sBCC Completed NCT00432185 Phase 2 PEP005
13 Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Superficial Basal Cell Carcinoma Completed NCT00108134 Phase 2 PEP005
14 Photodynamic Therapy Using Methyl-5-Aminolevulinate Hydrochloride Cream in Determining Pain Threshold in Patients With Skin Cancer Completed NCT01292668 Phase 1 methyl-5-aminolevulinate hydrochloride cream;photodynamic therapy
15 Topical Imiquimod 5% Cream for Treatment of Cutaneous Neurofibromas in Adults With Neurofibromatosis 1 Completed NCT00865644 Phase 1 Imiquimod 5% Cream
16 Pulsed Dye Laser in Treating Superficial Basal Cell Carcinomas Completed NCT02125669 Not Applicable
17 Laser Assisted Drug Delivery in the Treatment of Superficial Non Melanoma Skin Cancer: a Randomized Controlled Trial Completed NCT03012009 Not Applicable MAL;lidocaine hydrochloride 2% with epinephrine
18 Cytodiagnosis of Basal Cell Carcinoma and Actinic Keratosis Using Papanicolaou and May-grunwald-giemsa Stained Tissue Smear Completed NCT00218868
19 Randomized Pilot Study of Treatment for BCC Using the Multiplex 595/1064 nm Laser Completed NCT02270645 Not Applicable
20 Compassionate Use of Metvix® (Methyl Aminolevulinate) Photodynamic Therapy (PDT) in Subjects With Field Actinic Keratoses, Large/Multiple Superficial Basal Cell Carcinomas (BCCs), or Bowen's Disease No longer available NCT00535080 Metvix (methyl aminolevulinate)
21 Curettage Versus Excision in Nodular and Superficial Basal Cell Carcinomas Suspended NCT00515970 Not Applicable
22 Cure Rates of Superficial Basal Cell Carcinoma (BCC) EDC Terminated NCT00994240 Not Applicable

Search NIH Clinical Center for Superficial Basal Cell Carcinoma

Genetic Tests for Superficial Basal Cell Carcinoma

Anatomical Context for Superficial Basal Cell Carcinoma

MalaCards organs/tissues related to Superficial Basal Cell Carcinoma:

41
Skin, T Cells

Publications for Superficial Basal Cell Carcinoma

Articles related to Superficial Basal Cell Carcinoma:

(show top 50) (show all 139)
# Title Authors Year
1
Cryosurgery + 5% 5-Fluorouracil for Treatment of Superficial Basal Cell Carcinoma and Bowen's Disease [Formula: see text]. ( 29457484 )
2018
2
Accuracy of dermoscopic criteria for the differentiation between superficial basal cell carcinoma and Bowen's disease. ( 29633377 )
2018
3
Comparison of long term cosmetic outcomes for different treatments of superficial basal cell carcinoma. ( 29753062 )
2018
4
Laser-assisted photodynamic therapy for superficial basal cell carcinoma and Bowen's Disease: a randomised intra-patient comparison between a continuous and a fractional ablative CO<sub>2</sub> laser mode. ( 29633367 )
2018
5
Is a single day patient friendly methyl aminolevulinate photodynamic therapy illumination scheme for superficial basal cell carcinoma feasible? A randomized multicenter pilot trial. ( 29862877 )
2018
6
Reevaluating Mohs Surgery Appropriate Use Criteria for Primary Superficial Basal Cell Carcinoma. ( 29516099 )
2018
7
Ambulatory Photodynamic Therapy for Superficial Basal Cell Carcinoma: An Effective Light Source? ( 28093601 )
2017
8
Topical Sinecatechins, 10%, Ointment for Superficial Basal Cell Carcinoma: A Randomized Clinical Trial. ( 28793140 )
2017
9
Standard step sectioning of skin biopsy specimens diagnosed as superficial basal cell carcinoma frequently yields deeper and more aggressive subtypes. ( 28088999 )
2017
10
Five-Year Results of a Randomized Controlled Trial Comparing Effectiveness of Photodynamic Therapy, Topical Imiquimod, and Topical 5-Fluorouracil in Patients with Superficial Basal Cell Carcinoma. ( 29045820 )
2017
11
Photodynamic therapy with epidermal ablation using fractional CO2 laser for treating superficial basal cell carcinoma: A case series. ( 28647617 )
2017
12
Patient preferences for the attributes of a non-invasive treatment for superficial Basal cell carcinoma: a discrete choice experiment. ( 28667739 )
2017
13
Superficial basal cell carcinoma: A comparison of superficial only subtype with superficial combined with other subtypes by age, sex and anatomic site in 3150 cases. ( 28493477 )
2017
14
Superficial basal cell carcinoma: Dermoscopic and histopathological features of multiple small erosions. ( 28677117 )
2017
15
A novel clinical sign to aid in the diagnosis of superficial basal cell carcinoma. ( 29132860 )
2017
16
Treatment of superficial basal cell carcinoma by topical photodynamic therapy with fractionated 5-aminolevulinic acid 20% versus two stage topical methylaminolevulinic acid: results of a randomized controlled trial. ( 28886209 )
2017
17
Superficial basal cell carcinoma treated with 70% trichloroacetic acid applied topically: a case study. ( 28260938 )
2017
18
Treatment of superficial basal cell carcinoma with ingenol mebutate gel, 0.05%. ( 27574458 )
2016
19
Ablative Fractional Laser-Assisted Topical Fluorouracil for the Treatment of Superficial Basal Cell Carcinoma and Squamous Cell Carcinoma In Situ: A Follow-Up Study. ( 27359199 )
2016
20
Two-fold illumination in topical 5-aminolevulinic acid (ALA)-mediated photodynamic therapy (PDT) for superficial basal cell carcinoma (sBCC): A retrospective case series and cohort study. ( 26774689 )
2016
21
Superficial Basal Cell Carcinoma on the Face is a Diagnostic Challenge. ( 27057051 )
2016
22
Preoperative prediction of histopathologic outcome in basal cell carcinoma - flat surface and multiple small erosions predict superficial basal cell carcinoma in lighter skin types. ( 26921200 )
2016
23
Superficial basal cell carcinoma. ( 27914672 )
2016
24
Reflectance confocal microscopy and dermoscopy for in vivo, non-invasive skin imaging of superficial basal cell carcinoma. ( 27123056 )
2016
25
The effect of topical diclofenac 3% and calcitriol 3A I1g/g on superficial basal cell carcinoma (sBCC) and nodular basal cell carcinoma (nBCC): A phase II, randomized controlled trial. ( 27067393 )
2016
26
Three year follow-up results of photodynamic therapy versus imiquimod versus fluorouracil for treatment of superficial basal cell carcinoma: a single blind, non-inferiority, randomized controlled trial. ( 27113429 )
2016
27
Accuracy of optical coherence tomography for the diagnosis of superficial basal cell carcinoma - a prospective, consecutive, cohort study of 168 cases. ( 27146027 )
2016
28
Treatment failure in superficial basal cell carcinoma following treatment with photodynamic therapy: is this a result of underdiagnosis? ( 27256516 )
2016
29
Superficial Basal Cell Carcinoma Treated with Two Cycles of Ingenol Mebutate Gel 0.015. ( 27904293 )
2016
30
Surgery Versus 5% Imiquimod for NodularA and Superficial Basal Cell Carcinoma: 5-Year Results of the SINSA Randomized Controlled Trial. ( 27932240 )
2016
31
Treatment of superficial basal cell carcinoma and squamous cell carcinoma in situ on the trunk and extremities with ablative fractional laser-assisted delivery of topical fluorouracil. ( 25687314 )
2015
32
New I+-papillomavirus 4 isolate in a verruca vulgaris with multicentric superficial basal cell carcinoma. ( 25557421 )
2015
33
Commentary on 'Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial'. ( 25581586 )
2015
34
The importance of superficial basal cell carcinoma in a retrospective study of 139 patients who underwent Mohs micrographic surgery in a Brazilian university hospital. ( 26602517 )
2015
35
Response to 'Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial: a critical appraisal'. ( 25581585 )
2015
36
Pulsed dye laser treatment of superficial basal cell carcinoma. ( 25776237 )
2015
37
The choice and measurement of fluence in photodynamic therapy for superficial basal cell carcinoma. ( 26146762 )
2015
38
Tumor thickness and adnexal extension of superficial basal cell carcinoma (sBCC) as determinants of treatment failure for methylaminolevulinate (MAL)-photodynamic therapy (PDT), imiquimod, and 5-fluorouracil (FU). ( 25935596 )
2015
39
Patient Perception of Imiquimod Treatment for Actinic Keratosis and Superficial Basal Cell Carcinoma in 202 Patients. ( 25925162 )
2015
40
Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial: a critical appraisal. ( 25581584 )
2015
41
Subcutaneous Sarcoidal Granuloma Underlying Superficial Basal Cell Carcinoma. ( 26677309 )
2015
42
Treatment of choice in superficial basal cell carcinoma. ( 25776243 )
2015
43
The choice and measurement of fluence in photodynamic therapy for superficial basal cell carcinoma: reply from the authors. ( 26154079 )
2015
44
Melanoma in situ or superficial basal cell carcinoma? ( 26158373 )
2015
45
Immunocryosurgery for Non-superficial Basal Cell Carcinoma: A Pro-spective, Open-label Phase III Study for Tumours a8oa882 cm in Diameter. ( 23722308 )
2014
46
Biallelic alterations of the large tumor suppressor 1 (LATS1) gene in infiltrative, but not superficial, basal cell carcinomas in a Japanese patient with nevoid basal cell carcinoma syndrome. ( 25119020 )
2014
47
Discordant expression of desmoglein 2 and 3 at the mRNA and protein levels in nodular and superficial basal cell carcinoma revealed by immunohistochemistry and fluorescent in situ hybridization. ( 24934917 )
2014
48
A case of scrotal superficial basal cell carcinoma caused by chronic arsenic exposure. ( 24566581 )
2014
49
The role of the 595-nm pulsed dye laser in treating superficial basal cell carcinoma: outcome of a double-blind randomized placebo-controlled trial. ( 25040296 )
2014
50
Surgical excision versus imiquimod 5% cream for nodular and superficial basal-cell carcinoma (SINS): a multicentre, non-inferiority, randomised controlled trial. ( 24332516 )
2014

Variations for Superficial Basal Cell Carcinoma

Expression for Superficial Basal Cell Carcinoma

Search GEO for disease gene expression data for Superficial Basal Cell Carcinoma.

Pathways for Superficial Basal Cell Carcinoma

Pathways related to Superficial Basal Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 14)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.55 TLR7 TLR8 TLR9
2
Show member pathways
12.24 BLK TLR7 TLR8 TLR9
3
Show member pathways
12.14 TLR7 TLR8 TLR9
4
Show member pathways
12.04 TLR7 TLR8 TLR9
5
Show member pathways
11.93 TLR7 TLR8 TLR9
6
Show member pathways
11.91 TLR7 TLR8 TLR9
7
Show member pathways
11.87 BLK TLR7 TLR8 TLR9
8
Show member pathways
11.8 TLR7 TLR8 TLR9
9
Show member pathways
11.77 TLR8 TLR9
10 11.76 TLR7 TLR8 TLR9
11
Show member pathways
11.59 TLR7 TLR8 TLR9
12 11.44 BLK TLR7 TLR8 TLR9
13 11.38 TLR7 TLR9
14 11.26 TLR7 TLR8 TLR9

GO Terms for Superficial Basal Cell Carcinoma

Cellular components related to Superficial Basal Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 endoplasmic reticulum membrane GO:0005789 9.54 TLR7 TLR8 TLR9
2 Golgi membrane GO:0000139 9.5 TLR7 TLR8 TLR9
3 endosome membrane GO:0010008 9.33 TLR7 TLR8 TLR9
4 phagocytic vesicle GO:0045335 9.26 TLR7 TLR9
5 early phagosome GO:0032009 8.96 TLR7 TLR9
6 endolysosome membrane GO:0036020 8.8 TLR7 TLR8 TLR9

Biological processes related to Superficial Basal Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 22)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 9.9 PTCH1 TLR7 TLR8 TLR9
2 immune system process GO:0002376 9.77 TLR7 TLR8 TLR9
3 inflammatory response GO:0006954 9.73 TLR7 TLR8 TLR9
4 innate immune response GO:0045087 9.73 BLK TLR7 TLR8 TLR9
5 defense response to virus GO:0051607 9.61 TLR7 TLR8
6 cellular response to mechanical stimulus GO:0071260 9.58 TLR7 TLR8
7 positive regulation of inflammatory response GO:0050729 9.58 TLR7 TLR9
8 regulation of protein phosphorylation GO:0001932 9.57 TLR7 TLR8
9 positive regulation of interleukin-6 production GO:0032755 9.55 TLR7 TLR9
10 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.54 TLR7 TLR9
11 toll-like receptor signaling pathway GO:0002224 9.54 TLR7 TLR8 TLR9
12 positive regulation of interleukin-8 production GO:0032757 9.52 TLR7 TLR9
13 positive regulation of chemokine production GO:0032722 9.51 TLR7 TLR9
14 MyD88-dependent toll-like receptor signaling pathway GO:0002755 9.5 TLR7 TLR8 TLR9
15 microglial cell activation GO:0001774 9.49 TLR7 TLR8
16 I-kappaB phosphorylation GO:0007252 9.48 TLR7 TLR9
17 regulation of cytokine secretion GO:0050707 9.46 TLR8 TLR9
18 toll-like receptor 9 signaling pathway GO:0034162 9.43 TLR7 TLR8 TLR9
19 positive regulation of interleukin-8 biosynthetic process GO:0045416 9.4 TLR7 TLR8
20 positive regulation of interferon-gamma biosynthetic process GO:0045078 9.33 TLR7 TLR8 TLR9
21 positive regulation of interferon-beta biosynthetic process GO:0045359 9.13 TLR7 TLR8 TLR9
22 positive regulation of interferon-alpha biosynthetic process GO:0045356 8.8 TLR7 TLR8 TLR9

Molecular functions related to Superficial Basal Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 drug binding GO:0008144 9.32 TLR7 TLR8
2 double-stranded RNA binding GO:0003725 9.26 TLR7 TLR8
3 single-stranded RNA binding GO:0003727 9.16 TLR7 TLR8
4 transmembrane signaling receptor activity GO:0004888 9.13 TLR7 TLR8 TLR9
5 siRNA binding GO:0035197 8.62 TLR7 TLR9

Sources for Superficial Basal Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....